The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Human HIF‐3α4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma
Abstract
A universal response to changes in cellular oxygen tension is governed by a family of heterodimeric transcription factors called hypoxia‐inducible factor (HIF). Tumor hypoxia, as well as various cancer‐causing mutations, has been shown to elevate the level of HIF‐1α, signifying a critical role of the HIF pathway in cancer development. The recently identified third member of the human HIF‐α family, HIF‐3α, produces multiple splice variants that contain extra DNA binding elements and protein‐protein interaction motifs not found in HIF‐1α or HIF‐2α. Here we report the molecular cloning of the alternatively spliced human HIF‐3α variant HIF‐3α4 and show that it attenuates the ability of HIF‐1 to bind hypoxia‐responsive elements located within the enhancer/promoter of HIF target genes. The overexpression of HIF‐3α4 suppresses the transcriptional activity of HIF‐1 and siRNAmediated knockdown of the endogenous HIF‐3α4 increases transcription by hypoxia‐inducible genes. HIF‐3α4 itself is oxygen‐regulated, suggesting a novel feedback mechanism of controlling HIF‐1 activity. Furthermore, the expression of HIF‐3α4 is dramatically down‐regulated in the majority of primary renal carcinomas. These results demonstrate an important dominant‐negative regulation of HIF‐1‐mediated gene transcription by HIF‐3α4 in vivo and underscore its potential significance in renal epithelial oncogenesis. Maynard, M. A., Evans, A. J., Hosomi, T., Hara, S., Jewett, M. A. S., Ohh, M. Human HIF‐3α4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma. FASEB J. 19, 1396–1406 (2005)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
Regulation of Mammalian O 2 Homeostasis by Hypoxia-Inducible Factor 1
Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914 · cited 1×
“The transactivation property of HIF is in concert with the binding of transcriptional coactivators such as p300/ CBP to CAD of HIF- ( 1-3 ).”
BackgroundOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citationLaughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 1×
“For example, loss of p53 in various tumors or increased expression of HER2 receptor tyrosine kinase in breast cancer enhances HIF-1 expression and intensifies HIF-1-dependent transcription, often correlating with tumor aggressiveness (9, 10 ).”
BackgroundDimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1
Jiang, B.-H., Rue, E., Wang, G. L., Roe, R., & Semenza, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17771 · Cited by 1,106 · cited 2×
“required for heterodimerization and DNA binding (4).”
BackgroundRegulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
Loss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705
Cited by
Grubman, A., Chew, G., Ouyang, J. F., Sun, G., Choo, X. Y., McLean, C., Simmons, R. K., Buckberry, S., Vargas-Landin, D. B., Poppe, D., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0539-4 · Cited by 956
Transcriptional regulation by hypoxia inducible factors
Dengler, V. L., Galbraith, M. D., & Espinosa, J. M. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.838205 · Cited by 782
Elvidge, G. P., Glenny, L., Appelhoff, R. J., Ratcliffe, P. J., Ragoussis, J., & Gleadle, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511408200 · Cited by 464
Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation
Ramakrishnan, S., Anand, V., & Roy, S. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9531-7 · Cited by 442
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
Schödel, J., Grampp, S., Maher, E. R., Moch, H., Ratcliffe, P. J., Russo, P., & Mole, D. R. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.007 · Cited by 405
The VHL/HIF axis in clear cell renal carcinoma
Shen, C., & Kaelin, W. G. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.001 · Cited by 388
MicroRNA-210: A unique and pleiotropic hypoxamir
Chan, S. Y., & Loscalzo, J. (2010) · Cell Cycle · doi:10.4161/cc.9.6.11006 · Cited by 357
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Kaelin, W. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1865 · Cited by 336
miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target
Serocki, M., Bartoszewska, S., Janaszak-Jasiecka, A., Ochocka, R. J., Collawn, J. F., & Bartoszewski, R. (2018) · Angiogenesis · doi:10.1007/s10456-018-9600-2 · Cited by 288
Hypoxia-inducible factor 3 biology: complexities and emerging themes
Duan, C. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00315.2015 · Cited by 269
Zdzisińska, B., Żurek, A., & Kandefer-Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0406-x · Cited by 221
Roles of the human hypoxia-inducible factor (HIF)-3α variants in the hypoxia response
Heikkilä, M., Pasanen, A., Kivirikko, K. I., & Myllyharju, J. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0679-5 · Cited by 213
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1978-z · Cited by 99
Ravenna, L., Salvatori, L., & Russo, M. A. (2016) · The FEBS Journal · doi:10.1111/febs.13572 · Cited by 97
Janaszak-Jasiecka, A., Bartoszewska, S., Kochan, K., Piotrowski, A., Kalinowski, L., Kamysz, W., Ochocka, R. J., Bartoszewski, R., & Collawn, J. F. (2016) · Scientific Reports · doi:10.1038/srep22775 · Cited by 81
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
Tolonen, J.-P., Heikkilä, M., Malinen, M., Lee, H.-M., Palvimo, J. J., Wei, G.-H., & Myllyharju, J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03387-9 · Cited by 63
Identification of oleoylethanolamide as an endogenous ligand for HIF-3α
Diao, X., Ye, F., Zhang, M., Ren, X., Tian, X., Lu, J., Sun, X., Hou, Z., Chen, X., Li, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30338-z · Cited by 51
Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
Regulation of the HIF switch in human endothelial and cancer cells
Slawski, J., Jaśkiewicz, M., Barton, A., Kozioł, S., Collawn, J. F., & Bartoszewski, R. (2024) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2024.151386 · Cited by 26
Associations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
HIF inhibition: Current strategies and clinical challenges
Więch-Walów, A., Bartoszewska, S., Barton, A., Czechowicz, P., Dudzik, J., Wielockx, B., Collawn, J. F., & Bartoszewski, R. (2026) · Redox biology · doi:10.1016/j.redox.2026.104220 · Cited by 3
“Because many HIF-3 α isoforms are themselves induced by HIF-1 and HIF-2 [110], these findings led to a proposed negative-feedback model in which HIF-3 α attenuates HIF-dependent transcription [106, 110,111].”
Metadata
- Authors
- Maynard, M. A., Evans, A. J., Hosomi, T., Hara, S., Jewett, M. A. S., & Ohh, M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2005-09
- Volume
- 19
- Issue
- 11
- Pages
- 1396-1406
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2102365921
- Cited by
- 193
- References
- 15
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.